Lexaria Bioscience says dosing in first human trial of DehydraTECH CBD to treat high blood pressure has started

It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun

The first trial is a randomized, double-blinded, controlled human clinical study expected to involve 24 volunteers with symptoms of either pre-hypertension or mild hypertension

Lexaria Bioscience Corp () () revealed that its first human clinical trial assessing its DehydraTECH CBD technology to treat high blood pressure - HYPER-H21-1 - is now officially underway. 

It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun, the company told investors. 

READ: Lexaria Bioscience says DehyrdaTECH CBD client's product featured in New Hope Network best of 2020 list 

"Dosing is expected to be completed, on schedule, within several weeks, and we may be in a position to report preliminary data in July or thereabouts," said Chris Bunka, Lexaria CEO.

"Despite challenges in launching a human clinical study during a global pandemic, Lexaria’s Europe-based research partners have done an excellent job of balancing the need for scientific validation for a potential new hypertension treatment, with the required safety protocols currently in place."

Continue reading

Lexaria Bioscience says DehyrdaTECH CBD client's product featured in New Hope Network best of 2020 list

Lexaria provided Amari with its DehydraTECH technology, which delivers CBD to the body more quickly and effectively than traditional formulations

Hundreds of CBD products competed to be among those named in "New Hope Network Editors' Top Picks for 2020,” published in January 2021

Lexaria Bioscience Corp (NASDAQ:LEXX) () announced that its corporate client Amari Corp's "Everyday Calm" CBD product was named a Top CBD Product Pick by New Hope Network, host of the industry-leading Natural Products Expo conference events.  

Lexaria provided Amari with its DehydraTECH technology, which delivers CBD to the body more quickly and effectively than traditional formulations, as shown in repeated studies. 

"Lexaria is delighted to have been able to work with Amari and their award-winning products," Lexaria CEO Chris Bunka said in a statement. "DehydraTECH is gaining more widespread consumer support, and we expect to see products utilizing DehydraTECH technology in more and more stores across America as the year unfolds." 

READ: Lexaria Bioscience to evaluate DehydraTECH in four drug markets

Hundreds of CBD products competed to be among those named in "New Hope Network Editors' Top Picks for 2020,” published in January 2021, the company said.

Continue reading

Lexaria Bioscience to evaluate DehydraTECH in four drug markets

The new study programs will target NSAIDs, nicotine replacement therapies, tetrahydrocannabinol (THC), and erectile dysfunction 

Each study will evaluate the rate of absorption and speed (pharmacokinetics or PK assessments)

Lexaria Bioscience Corp (NASDAQ:LEXX) (), a global innovator in drug delivery platforms, said Tuesday it will begin important new applied research and development study programs.  

In a statement, the company said the new study programs will target four-drug markets, including NSAIDs, nicotine replacement therapies, tetrahydrocannabinol (THC), and erectile dysfunction. 

Lexaria added that each study will evaluate the rate of absorption and speed (pharmacokinetics or PK assessments) with which various new enhanced DehydraTECH experimental formulations – DehydraTECH 2.0 – deliver the drugs into the bloodstream and, in some cases the brain, after oral dosing. 

READ: Lexaria technology generates positive stability testing for ready-to-drink CBD beverages

“Our 2021 study program – already the largest in our company’s history – is growing,” said CEO Chris Bunka. “All of our studies are designed to generate must-have data, allowing us to have more meaningful business discussions with various industry leaders and as such, can shorten the time required for positive commercial developments.”

Continue reading

Lexaria Bioscience receives positive test results from ready to drink CBD beverages

Lexaria Bioscience (CSE: LXX- Nasdaq: LEXXW) CEO Chris Bunka joined Steve Darling from Proactive to share news the company has released positive results from its extended stability testing for bottled CBD-containing beverages prepared using its technology.

Bunka telling Proactive Lexaria’s DehydraTECH CBD nanoemulsification formulation and processing techniques tested in beverages maintained their CBD content which was verified at 93.4% of target potency one year after production and also evidenced excellent microbial purity over this period.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading

Lexaria technology generates positive stability testing for ready-to-drink CBD beverages

The company reported that by using its DehydraTECH technology CBD beverages demonstrated 93.4% potency one year after production

Lexaria's first patent was awarded in 2016 for CBD-infused beverages and consumable liquids

Lexaria Bioscience Corp (NASDAQ:LEXX) () shared Wednesday positive results from its extended stability testing, which showed unparalleled stability for bottled CBD drinks made using its technology. 

The Kelowna, British Columbia-based company’s patented DehydraTECH cannabidiol (CBD) nano-emulsification formulation and processing techniques, ensured the tested beverages maintained their CBD content, which was verified at 93.4% of target potency one year after production. The drinks also had “excellent microbial purity over this period,” said the company. 

In addition, the DehydraTECH ready-to-drink (RTD) beverages were tested for content uniformity and homogeneity of CBD distribution and demonstrated “less than 1% variability” in CBD potency in fractions sampled from the top, middle, and bottom of the drink without physical mixing. 

READ: Lexaria Bioscience reports progress in two antiviral drug studies in its 2021 applied R&D program

"I love reminding people that Lexaria's first patent was awarded in 2016 for CBD-infused beverages and consumable liquids," Lexaria CEO Chris Bunka said in a statement.

Continue reading

Lexaria Bioscience reports progress in two antiviral drug studies in its 2021 applied R&D program

Two of the four planned studies using DehydraTECH with antivirals are progressing -- comprised of a SARS-CoV-2 infected human cell culture study (VIRAL-C21-3) and an animal research pharmacokinetic study (VIRAL-A20-2)

The drugs being studied in Lexaria’s 2021 antiviral program not only target SARS-CoV-2/COVID 19 applications, but also have existing utility across additional infectious diseases

Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) (OTCMKTS:LXR) announced Tuesday extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development (R&D) program.

“It’s been a very productive start into 2021 with a total of seven studies across our various research programs currently underway,” said Lexaria CEO Chris Bunka in a statement.

READ: Lexaria Bioscience updates on progress of its DehydraTECH CBD studies to treat high blood pressure

“Lexaria’s applied R&D programs are vital to generate the supportive data required to pursue either regulatory approvals or corporate relationships necessary for commercial launch. We expect great success this year and are eager to report study results as they become available,” Bunka added.

The company said that two of the four planned studies using DehydraTECH with antivirals are progressing -- comprised of one SARS-CoV-2 infected human cell culture study (VIRAL-C21-3) and one animal research pharmacokinetic study (VIRAL-A20-2).

Continue reading

Lexaria provides update on 5 studies focussed on DehydraTECH CBD as a treatment for hypertension

Lexaria Bioscience (CSE: LXX-NASDAQ: LEXX- OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive to share details about the company’s three human clinical trials and two animal research trials. Bunka telling Proactive how these studies are going so far. The studies are using Lexaria’s DehydraTECH CBD for the treatment of hypertension and are being performed by third-party laboratories to ensure study objectivity.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria Bioscience updates on progress of its DehydraTECH CBD studies to treat high blood pressure

In human study HYPER-H21-1, the recruiting of 24 volunteers with otherwise untreated pre- or mild-hypertension has begun, and dosing using a single 300mg dose of CBD with or without DehydraTECH formulation enhancement is tentatively expected to be completed by May this year

Lexaria noted that the US annual hypertension drug market is worth US$28 billion, with direct healthcare costs for patients with pulmonary arterial hypertension estimated at between US$29,712 and $142,500 per year

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) has updated investors on the progress of assessing its DehydraTECH CBD technology in treating high blood pressure, noting that all five of its planned studies for this year are now underway.

Three human clinical trials and two animal research studies are in progress.

READ: Lexaria Bioscience expands DehydraTECH CBD hypertension program with two new human trials; updates for others

In the human study HYPER-H21-1, the recruiting of 24 volunteers with otherwise untreated pre- or mild-hypertension has begun, and dosing using a single 300mg dose of CBD with or without DehydraTECH formulation enhancement, is tentatively expected to be completed by May this year.

In human trial HYPER-H21-2, formal hospital and ethics board applications for an upcoming European study have been approved and test articles are expected to arrive at the research site as early as next week.  Following this, recruitment of 16 volunteers will start soon, said Lexaria.

Continue reading

Lexaria Bioscience expands DehydraTECH CBD hypertension program with two new human trials; updates for others

Study design for HYPER-A21-1 and HYPER-A21-2, both animal studies, has been completed, and dosing is expected to begin in late February or early March

Lexaria Bioscience Corp (NASDAQ:LEXX) () is expanding its applied research and development (R&D) program in 2021 with a particular focus on DehydraTECH-enabled CBD for hypertension, the company announced Thursday. 

The company’s hypertension program now consists of five planned studies, three of which were previously announced on February 1 (HYPER-A21-1, HYPER-A21-2, and HYPER-H21-1). Study design for HYPER-A21-1 and HYPER-A21-2, both animal studies, has been completed, and dosing is expected to begin in late February or early March.

HYPER-H21-1, as well as new additions HYPER-H21-2 and HYPER-H21-3, are randomized, double-blinded human clinical studies that will take place in Europe, the company said. Study design for HYPER-H21-1 is complete, and university hospital and ethics board approvals have been received. Dosing will begin after shipment of the clinical test articles to the clinical site is completed, pending regulatory clearances.

READ: Lexaria Bioscience plots applied R&D course to DehydraTECH CBD hypertension and antiviral studies

HYPER-H21-2 is designed to monitor ambulatory blood pressure during the 24-hour period after dosing, with subjects wearing portable devices that will record blood pressure at 30-minute and 60-minute intervals. Volunteers will receive a 150mg dose of DehydraTECH-CBD or a placebo three times daily. 

The company hopes that the results of this study will help it understand the effectiveness of DehydraTECH-processed CBD as a potential anti-hypertensive agent over a full day of monitoring, which complements the shorter-term monitoring in HYPER-H21-1. Study design for HYPER-H21-2 is complete and university hospital and ethics board approvals are pending.

Continue reading

After successful raise of 11 million dollars, Lexaria Bioscience spells out R&D program for 2021

Lexaria Bioscience (NASDAQ: LEXXW- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company is planning for a very busy 2021 with a number of research and development initiatives.

Bunka telling Proactive they are planning research on DehydraTECH-CBD For Hypertension and they are also looking at DehydraTECH with Antivirals for COVID-19.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading

Lexaria Bioscience plots applied R&D course to DehydraTECH CBD hypertension and antiviral studies

The new programs come on the heels of a recently-closed oversubscribed financing worth US$11 million

Lexaria’s prospective business partners expect evidence that demonstrates initial effectiveness of DehydraTECH in improving drug delivery characteristics prior to entering negotiations

Lexaria Bioscience Corp (NASDAQ:LEXX) () announced a pair of R&D programs Monday focused on DehydraTECH utilizing CBD for hypertension and antivirals to treat COVID-19.

The new programs come on the heels of a recently-closed oversubscribed financing worth US$11 million, which the company said has greatly enhanced its ability to conduct applied R&D designed to test the effectiveness of its patented DehydraTECH drug delivery technology across multiple classes of bioactive substances or drugs.

Lexaria’s prospective business partners expect evidence that demonstrates initial effectiveness of DehydraTECH in improving drug delivery characteristics prior to entering negotiations, the company said. As such, the company considers R&D studies to be a vital early step in establishing relationships with industry partners to utilize DehydraTECH in their product lines.

READ: Lexaria Bioscience bolsters board of directors with Al Reese Jr

Continue reading

Lexaria Bioscience's DehydraTECH drug delivery system can unlock more effective CBD — and may even help fight COVID-19

Novel drug delivery platform DehydraTECH masks unwanted tastes, improves onset speed, increases bioavailability of active ingredients Cannabis is the current focus, but company eyeing massive markets such as nicotine and painkillers Currently working on using DehydraTECH to deliver antiviral drugs and help in the global fight against coronavirus

Lexaria Bioscience Corp () () is a Canadian company with a patented technology that promises to change the way drugs are delivered into the body.

The Kelowna, British Columbia-based company has developed and markets DehydraTECH, which masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

In 2013, Lexaria’s management decided to pivot from oil to cannabis and within a year had acquired the rights to DeydraTECH, which is now the company’s main focus.

Essentially, DehydraTECH allows cannabidiol (CBD) and other oils to be dehydrated into an odourless, tasteless powder and mixed with xanthan gum, cornflour and other base ingredients which can then be added to foods, drinks and creams.

It also allows drugs and vitamins – in the case of cannabis, CBD – to enter the bloodstream faster than existing drug delivery platforms.

Continue reading

Lexaria Bioscience bolsters board of directors with Al Reese Jr

Reese has over 40 years' experience in public and private businesses and was finance chief at a former Nasdaq-listed energy company

"With the new capital and the right amount of capital discipline, Lexaria should have an excellent future," said Reese

Lexaria Bioscience Corp (NASDAQ:LEXX) (NASDAQ:LEXXW) () has bolstered its board with the addition of Al Reese Jr. 

Certified accountant Reese has over 40 years' experience in public and private businesses and was finance chief at a former Nasdaq-listed energy company, where he arranged transactions totaling more than US$10 billion over two decades. 

READ: Lexaria Bioscience prices $9.6M public offering as shares set to begin trading on the Nasdaq

"Al is also experienced in negotiating technology license agreements with companies in the US and internationally, and the board of directors looks forward to his guidance as Lexaria continues to evolve and pursue its strategic out-licensing business model," said Chris Bunka, CEO and chairman, at Lexaria.

Reese added in the statement: "I’ve been familiar with Lexaria since inception and have seen this team’s determination to develop and commercialize the DehydraTECH TM technology. 

Continue reading

Lexaria BioScience begins trading on the Nasdaq Exchange in the United States

Lexaria BioScience (NASDAQ: LEXX- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive to bring news the company is now trading on the Nasdaq capital markets. That includes an offering with gross proceeds of 9.6 million.

Bunka telling Proactive what has gotten the company to this point and why the move was made, He also talked about what he feels will be a big 2021 for Lexaria.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading

Lexaria Bioscience prices $9.6M public offering as shares set to begin trading on the Nasdaq

It intends to use the net proceeds of the offering, which includes a $1.44 million up-size option, for R&D studies, patent and legal costs, and general working capital purposes

Under the scheme, Lexaria is offering 1,828,571 units, with each unit consisting of one share and one warrant to purchase one share at US$5.25 per unit

Lexaria Bioscience Corp (NASDAQ:LEXX) (NASDAQ:LEXXW) () said its common stock and warrants will begin trading Tuesday (today) on the Nasdaq Capital Market under the ticker symbols 'LEXX' and 'LEXXW.'

In addition, the company also announced the pricing of an underwritten public offering that could raise up to about $11 million and intends to use the net proceeds for research and development studies, patent and legal costs associated, and general working capital purposes.

Under the scheme, Lexaria is offering 1,828,571 units, with each unit consisting of one share and one warrant to purchase one share at US$5.25 per unit. The shares of common stock and warrants comprising the units are immediately separable and will be issued separately, but will be purchased together. 

READ: Lexaria Bioscience orders additional coronavirus studies of antiviral drugs delivered using DehydraTECH

The warrants have an exercise price of $6.58 per share, are immediately exercisable, and will expire five years following the date of issuance. The company also has granted the underwriter H.C. Wainwright & Co a 30-day option to purchase up to an additional 274,285 shares of common stock and/or warrants to purchase up to 274,285 shares of common stock.

Continue reading

Lexaria Bioscience orders additional coronavirus studies of antiviral drugs delivered using DehydraTECH

Lexaria has commissioned studies to evaluate DehydraTECH’s ability to enhance the delivery and efficacy of four additional antiviral drugs, including remdesivir

A previous study demonstrated that DehydraTECH significantly improved drug delivery in animals of two classes of antiviral therapies under investigation for the treatment of the coronavirus

Lexaria Bioscience Corp () () announced Tuesday that following promising antiviral study results earlier this month, the company has initiated the next phase of research on its DehydraTECH drug delivery platform  

The previous study demonstrated that DehydraTECH significantly improved drug delivery in animals of two classes of antiviral therapies, a protease inhibitor and a reverse transcriptase inhibitor, both of which are under investigation for the treatment of the coronavirus. 

Now, Lexaria has commissioned studies to evaluate DehydraTECH’s ability to enhance the delivery and efficacy of four additional antiviral drugs, including remdesivir, a nucleotide reverse transcriptase inhibitor (NtRTI) approved by the US Food and Drug Administration (FDA) in October for the treatment of coronavirus in cases of hospitalization. 

READ: Lexaria Bioscience closes sale of its non-pharmaceutical THC-related assets to Hill Street Beverage

The studies will administer DehydraTECH-enabled formulations to male rats to quantify and compare total drug delivery into the rodent bloodstream against control formulations. These studies will be conducted by a third-party pharmacokinetic testing laboratory in Pennsylvania, the company said.

Continue reading

Lexaria Bioscience closes sale of its non-pharmaceutical THC-related assets to Hill Street Beverage

The biotechnology company has agreed last month to sell the assets owned by its subsidiary Lexaria Canpharm for C$3.85 million to Hill Street, in which Lexaria owns a large position

Lexaria said the asset sale was one of the larger objectives needed as it seeks to list its securities on a national US securities exchange

Lexaria Bioscience Corp () (OTCMKST:LXRP) announced Thursday that it has closed the sale of its non-pharmaceutical THC-related assets. 

The biotechnology company has agreed last month to sell the assets owned by its subsidiary Lexaria Canpharm ULC for C$3.85 million to Hill Street Beverage Company Inc (), in which Lexaria owns a large position.

Lexaria said the asset sale was one of the larger objectives needed as the company seeks to list its securities on a national US securities exchange. 

READ: Lexaria Bioscience encouraged by study results using its DehydraTECH platform to deliver antiviral drugs

Under the purchase agreement, Lexaria has received C$350,000 in cash and 6,031,363 restricted common shares of Hill Street at C$0.0829 per share as the first required equity-based payment. It also has received a promissory note having a principal amount of C$2 million and bearing interest at the rate of 10% per annum, and a limited license to use the DehydraTECH technology outside of Canada and the US for certain non-pharmaceutical, therapeutic, and medicinal products that contain 0.3% or greater THC. 

Continue reading

Lexaria Bioscience proves technology works in enhancing oral delivery of antiviral drugs

Lexaria Bioscience (OTCQX:LXRP-CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company has announced that its DehydraTECH technology significantly improved delivery in study animals of representative drugs from two classes of antiviral therapies.

Bunka telling Proactive what this step means for the company and where they plan on taking this in 2021.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading

Lexaria Bioscience encouraged by study results using its DehydraTECH platform to deliver antiviral drugs

The company's technology was found to "significantly" improve the delivery of two classes of antiviral drugs - a protease inhibitor and a reverse transcriptase inhibitor

"DehydraTECH is a powerful technology that has now been shown effective through animal testing with antiviral drugs, nicotine and cannabinoids demonstrating its versatility to enhance delivery of lipophilic drugs to the bloodstream"

Lexaria Bioscience Corp () () has reported encouraging early results of studies, which used its DehydraTECH platform to deliver antiviral drugs to animals. 

The company's technology was found to "significantly" improve the delivery of two classes of antiviral drugs - a protease inhibitor and a reverse transcriptase inhibitor. 

READ: Lexaria Bioscience sells THC-related assets for C$3.85 million to Hill Street Beverage Company ahead of possible US listing

The findings augur well for the original antiviral therapeutic indications of the drugs that were studied here as well as for other antiviral drugs within their classes for indications, including to treat the coronavirus (COVID-19), said the company. 

"We are very pleased to have demonstrated improvements in DehydraTECH's delivery of antiviral drugs in animal bloodstream in our very first attempt to do so," said Chris Bunka, CEO of Lexaria in a statement.

Continue reading

Lexaria Bioscience agrees to sell non-pharmaceutical THC related assets for 3.85 million

Lexaria Bioscience (CSE: LXX- OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has agreed to sell certain non-core, non-pharmaceutical THC-related business assets to Hill Street Beverage for 3.85 million Canadian.

Bunka also told Proactive “Hill Street is acquiring royalty-free and perpetual global rights including relicensing rights of Lexaria's DehydraTECH technology” He also said Lexaria retains full ownership of its DehydraTECH technology.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading